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From the paradigm shifting observations of Harvey, Malpighi, and van Leeuwenhoek, blood 
vessels have become recognized as distinct and dynamic tissue entities that merge with the 
heart to form a closed circulatory system.1 Vessel structures are comprised predominantly of 
a luminal layer of endothelial cells that is surrounded by some form of basement membrane, 
and mural cells (pericytes or vascular smooth muscle cells) that make up the vessel wall. In 
larger more complex vessel structures the vessel wall is composed of a complex interwoven 
matrix with nerve components. Understanding the cellular and molecular basis for the 
formation, remodeling, repair, and regeneration of the vasculature have been and continue to 
be popular areas for investigation.
The endothelium has become a particularly scrutinized cell population with the recognition 
that these cells may play important roles in maintaining vascular homeostasis and in the 
pathogenesis of a variety of diseases.2 Although it has been known for several decades that 
some shed or extruded endothelial cells enter the circulation as apparent contaminants in the 
human blood stream,3 only more recent technologies have permitted the identification of not 
only senescent sloughed endothelial cells,4 but also endothelial progenitor cells (EPCs), 
which have been purported to represent a normal component of the formed elements of 
circulating blood5 and play roles in disease pathogenesis.6–9 Most citations refer to an article 
published in 1997 in which Asahara and colleagues isolated, characterized, and examined 
the in vivo function of putative EPCs from human peripheral blood as a major impetus for 
generating interest in the field.10 This seminal article presented some evidence to consider 
emergence of a new paradigm for the process of neovascularization in the form of postnatal 
vasculogenesis. Since publication of that article, interest in circulating endothelial cells, and 
particularly EPCs, has soared, and one merely has to type the keyword search terms, 
endothelial progenitor cell, to recover more than 8984 articles including 1347 review articles 
in PubMed (as of June 2008).
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What can we possibly add in the form of another EPC review that will be considered of 
significant value for the reader? We will attempt to review some of the early article in the 
field and reflect on how information in those articles was gradually derivatized into perhaps 
more conflicting rather than unifying concepts. We will also attempt to concisely address 
some of the important determinants and principles that are now leading to a new 
understanding of what functionally constitutes an EPC and outline some of the current 
measures used to identify, enumerate, and quantify these cells. Finally, we give our opinion 
of the best definition for an EPC based on some comparative analyses performed primarily 
in human subjects.
EPC Identity and Phenotype
There are a variety of measures that one can use to assist in the isolation and quantification 
of EPCs, but these can be simplified into two approaches: in vitro adhesion and growth 
(Figure 1) and selection by cell surface phenotype using fluorescent labeled antibodies and 
flow cytometry (Figure 2). First, we must confess that even at the time of writing this review, 
to our knowledge, no one has identified specific unique cell surface molecules that permit 
prospective isolation of an EPC in human or any other vertebrate species. That said, 
remarkable progress has been made in our understanding that there are numerous cell types 
and lineages that participate in neovascularization during development, at homeostasis, and 
during disease. Despite the lack of a unifying phenotype for an EPC, an approach for 
addressing how all these cells and cell lineages participate in the process is emerging and has 
provided new strategies for enhancing or inhibiting the process of new blood vessel 
formation.
In Vitro Adhesion and Morphology
Asahara et al10 reasoned that cell surface molecules shared by angioblasts and hematopoietic 
stem cells (HSCs) might serve as a means to identify putative angioblasts circulating in adult 
peripheral blood. This rationale cannot be underestimated, as it was somehow largely 
underappreciated in many subsequent articles by others attempting to define human EPCs, 
but as new information has emerged, it has become apparent that most of the antigens 
currently selected as a marker for human EPCs fail to discriminate hematopoietic cells from 
EPCs. In the Asahara at al10 article, human CD34 expressing cells (15.7% enriched for 
CD34+ expression) in adult peripheral blood were interrogated as putative EPCs via in vitro 
and in vivo assays. While determining some of the unique aspects of putative EPCs in vitro, 
Asahara et al10 reported that the cells adhered to fibronectin-coated dishes with greater 
frequency than to type 1 collagen coated dishes and displayed a spindle-shaped morphology. 
Of interest, the putative CD34+ EPCs when cocultured with CD34+ depleted mononuclear 
cells formed clusters of round cells centrally and sprouts of spindle-shaped cells at the 
periphery. The adherent putative EPCs expressed a variety of cell surface proteins typically 
expressed by human umbilical vein endothelial cells and expression of these markers 
increased over time in vitro. Further studies provided evidence of these putative EPCs 
(CD34+ or vascular endothelial growth factor receptor 2 [Flk-1+] cells enriched to 20%) 
localizing to areas of neovascularization when injected in vivo into nude mice with induced 
hindlimb ischemia. Thus, in one article Asahara et al10 brought forth concepts of circulating 
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EPCs, in vitro observations of EPC behavior, in vivo migration of putative EPCs to sites of 
vascular injury, and the paradigm of postnatal vasculogenesis.
The description of a putative EPC forming clusters in vitro within 5 days from the Asahara 
et al10 article, was expanded on by Ito et al11 who isolated human peripheral blood 
mononuclear cells and plated the cells on fibronectin-coated dishes. After a 24-hour period 
of adhesion, nonadherent cells were removed and replated onto fibronectin-coated dishes 
and the number of clusters that emerged at 7 days of plating was enumerated as EPC-derived 
colonies. The rationale for preplating the mononuclear cells for 24 hours was to deplete the 
population of monocytes, macrophages, and any circulating mature endothelial cells that 
could contaminate the putative EPC assay system.
Hill et al12 further modified this cluster-forming assay, by preplating human peripheral 
blood mononuclear cells for 48 hours on fibronectin coated dishes and then replating the 
nonadherent cells to quantify the emergence of the EPC colony-forming units several days 
later. This assay is commercially available, and the putative EPCs (that produce the progeny 
that form the colony) have been referred to as colony forming unit-Hill (CFU-Hill; Figure 
1). The CFU-Hill assay has been used to demonstrate a significant inverse correlation 
between the circulating CFU-Hill concentration and Framing-ham cardiovascular risk score 
in human subjects.12
It is important to reflect on the differences between the methods of these three early articles 
in the field. Whereas Asahara et al10 plated minimally enriched CD34+ putative EPCs on 
fibronectin-coated dishes and simply observed the adherent cells forming “blood island-like” 
clusters of differentiating endothelial cells, Ito et al11 modified the assay conditions to screen 
for nonadherent mononuclear blood cells (after 24 hours of preplating) that formed the same 
kind of cluster formation and counted these as EPC-derived clusters. Hill et al12 modified 
the assay further by preplating the blood mononuclear cells for 48 hours and then replating 
the nonadherent cells and observed over several days for the appearance of the EPC colony 
forming unit cell that Hill et al12 interpreted as a quantitative readout of the EPCs. Thus, the 
only variable that tied these three studies together was the cluster morphology displayed by 
the blood mononuclear cells in vitro (Figure 1). It is not at all clear that the original 
minimally enriched CD34+ putative EPCs plated by Asahara et al10 and the CFU-Hill cells 
are related, and yet the inference is that these very different assays measure the presence of 
an EPC with the same functional properties.
Recently, we13 and others14,15 have demonstrated that plating human peripheral blood or 
umbilical cord blood mononuclear cells on fibronectin-coated plates (with or without 
preplating steps) in the commercial CFU-Hill media or other media optimized for growth of 
endothelial cells in vitro results in the appearance of colonies composed of an aggregate of 
round cells with spindle-shaped cells emerging from the base and radiating away from the 
core of the colony. These CFU-Hill appearing colonies have been demonstrated to be 
composed of round hematopoietic cells that include myeloid progenitor cells, monocytes, 
and T lymphocytes.13–15
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The spindle shaped cells radiating away from the core are macrophages that display many 
features of endothelial cells with regard to cell surface protein expression, endothelial nitric 
oxide production, and expression of angiogenic molecules. These spindle shaped cells 
expressing endothelial markers (representing previously defined EPCs) do not spontaneously 
form blood vessels when implanted in vivo in collagen gels (do not display postnatal 
vasculogenic activity) and readily ingest bacteria in keeping with their monocyte-
macrophage lineage roots.13 Thus, one of the central assays in the EPC field, which arose 
over several experimental modifications from the original observations of Asahara et al,10 
does not assay for a cell that can give rise to a lineage of endothelial progeny, but instead is 
actually composed of hematopoietic cells enriched for monocyte-macrophage or T cell 
lineage commitment. In other words, the CFU-Hill assay measures cell-to-cell interactions 
among hematopoietic cells, and during subsequent differentiation these hematopoietic cells 
are stimulated by the culture conditions to mimic many features of endothelial cells; the 
CFU-Hill assay fails to identify cells that directly display any postnatal vasculogenic activity 
and thus, by definition, CFU-Hill are not composed of EPC progeny and are not a measure 
of EPCs. This important clarification does not constitute an argument that CFU-Hill are not 
involved in neoangiogenesis or serve as a biomarker for cardiovascular outcomes, rather the 
point is made to simply and clearly reflect our current understanding that these colonies are 
hematopoietic in origin and function.
A second method to isolate and enumerate EPCs based on adhesion of peripheral blood 
mononuclear cells to fibronectin coated culture dishes was described by Vasa et al in 
2001.16,17 Low density mononuclear cells from peripheral human blood were plated on 
fibronectin and gelatin coated dishes in the presence of media supplemented with endothelial 
growth factors and fetal calf serum. After 4 days in culture, the nonadherent cells were 
removed, and the adherent cells were assessed for the ability to ingest acetylated low-density 
lipoprotein (LDL) or fluorescently labeled Ulex europaeus agglutinin 1 plant lectin (Figure 
1). The adherent cells that ingested or bound both antigens were considered EPCs and were 
counted. These adherent cells were released from culture and confirmed to express 
endothelial marker proteins von Willebrand factor (vWF), vascular endothelial cadherin, and 
vascular endothelial growth factor receptor 2 (FLk-1 for mice and KDR for human) by flow 
cytometry. An inverse relationship between the circulating concentration of these EPCs and 
increased risk factors for development of coronary artery disease in human subjects was 
reported.17
The above data suggest that any low-density blood mononuclear cells that adhere to the 
fibronectin- and gelatin-coated dishes and within 4 days express KDR, vWF, vascular 
endothelial cadherin, and bind acetylated LDL and Ulex lectin are EPCs. However, others 
have shown that similarly isolated and cultured adherent cells expressing the above antigens 
may also coexpress to varying degrees, CD45, CD11b, CD11c, CD14, CD68, eNOS, and E-
selectin, and they avidly ingest India ink similar to macrophages.13–15,18,19 The use of a 
panel of cell surface antigens alone may be inadequate to discriminate EPCs from 
macrophages because macrophages are well known to express “endothelial-specific” 
proteins, particularly when cultured in medium containing certain endothelial growth factors 
and fetal calf serum.20–24
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Furthermore, direct adhesion of peripheral blood mononuclear cells onto fibronectin- and 
gelatin-containing substrates is a published well recognized method to isolate enriched 
populations of peripheral blood monocytes (>90% enriched).25 Thus, a current summation 
of many studies to date suggests that direct adhesion of peripheral blood mononuclear cells 
to fibronectin (with or without gelatin)-coated dishes and culture of the adherent layer may 
highly enrich for monocytes and is certainly not specific for EPCs. Whether or not the 
monocytes, isolated in this manner, proceed to express “endothelial-specific” markers and 
participate in neoangiogenesis depends on the culture conditions and growth factors used. 
This fact in particular has led to some considerable confusion, suggesting to some 
investigators that monocytes become EPCs.26,27
However, a more plausible working hypothesis is that some monocyte–macrophage subsets 
are potent circulating regulators of the angiogenic response (and have been called circulating 
angiogenic cells [CAC]; Figure 1) and play important roles in vascular regulation at 
homeostasis, and initiation of neoangiogenesis during wound healing, tissue ischemia, tissue 
remodeling, and tumorigenesis without becoming an integral part of the endothelial 
intima.28–38
It is also possible that some macrophages, like trophoblast cells in the placenta,39 may 
transiently adhere to areas in the vasculature in which there is no endothelial covering 
(because of endothelial cell death or injury) and be in direct contact with the circulating 
blood, express a whole host of endothelial proteins, and function in some way for some 
period of time like an endothelial cell, without actually ever irreversibly committing to an 
endothelial cell fate (with loss of all macrophage and/or trophoblast properties). This is a 
theoretically significant problem if a macrophage moonlighting as an endothelial cell in vivo 
is confronted with a bacterial challenge or a cytokine storm during an acute innate response 
to an invading microorganism and resumes an inflammatory macrophage fate. This is also an 
interesting experimental question that has important implications for disease pathogenesis 
such as endothelial dysfunction in diabetes, aging, hypertension, and in the development of 
atherosclerosis. Finally, this new insight that the preponderance of studies evaluating 
putative EPCs may have been examining the role of hematopoietic-derived cells reconciles 
the considerable amount of undeniable experimental data that putative EPCs are marrow 
derived (which is, of course, the predominant site of hematopoiesis in the adults).
All of the above methods used mononuclear cell adhesion to a particular matrix substrate 
under relatively short term culture conditions to identify and enumerate populations of 
putative EPCs. As such, the clusters or colonies of cells that emerged were at one time 
referred to as early outgrowth colonies (Figure 1). Another distinctly different population of 
cells has been determined to emerge later in culture and at one time were referred to as late 
outgrowth colonies (Figure 1). This has also been a confusing point in the literature. 
Whereas the early outgrowth cells as described above have largely been determined to be 
hematopoietic cells, the later out-growth cells are clearly endothelial cells. At present, the 
early and late outgrowth terms have lost their usefulness as a means to discriminate between 
types of colonies and have largely been retired.
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Although the majority of endothelial cells that can be identified in circulating human blood 
are thought to be mature and even senescent sloughed endothelial cells, it has been reported 
that some rare endothelial cells demonstrate proliferative potential. Lin et al40 isolated 
peripheral blood mononuclear cells from a group of patients that had undergone sex-
mismatched bone marrow transplantation and reported that the endothelial cells that 
appeared in vitro within a week of plating the blood cells on type 1 rat tail collagen coated 
dishes displayed limited proliferative potential and were of host origin. In contrast, colonies 
of highly proliferative endothelial cells emerging 14 to 21 days later were of donor origin, 
suggesting a marrow origin. These blood outgrowth endothelial cells demonstrated greater 
than a 1000-fold expansion over a 2-month period in vitro. We13,41,42 and numerous other 
labs43–52 have confirmed this seminal article and moved forward to successfully isolate high 
proliferative endothelial colony forming cells from both umbilical cord blood and adult 
peripheral blood. Umbilical cord blood contains a higher concentration of these proliferative 
cells and the proliferative potential of the endothelial colony forming cells (ECFCs) is 
significantly greater (at a clonal level) than that observed for ECFCs isolated from adult 
peripheral blood.41
Although these cells display a host of typical antigens normally expressed on vascular 
endothelial cells, they do not express CD45, CD14, or CD115 and do not ingest bacteria. 
Furthermore, when suspended in gels of differing matrix compositions and implanted in vivo 
in the subcutaneous space of immunodeficient mice, these highly proliferative ECFCs 
(Figures 1 and 2) spontaneously form human blood vessels that inosculate with nearby 
murine vessels and become a part of the systemic circulation of the host mouse.13,49,53 Thus, 
ECFCs display properties of an EPC; cells that can clonally give rise to progeny that 
spontaneously form human blood vessels in vivo (postnatal vasculogenesis) and become a 
part of a circulatory system (Figures 1 and 2).
Recently, Sieveking et al54 have reported the development of a novel endothelial specific in 
vitro tubulogenesis assay that highlights striking differences in the properties of the putative 
EPCs as described by Asahara et al10 and the outgrowth endothelial colonies (emerging 14 
to 21 days after initial plating of blood mononuclear cells as described above) with high 
proliferative potential described by Lin et al.40 Human fetal lung fibroblasts were plated to 
confluence, and when human microvascular, coronary artery, or umbilical vein endothelial 
cells were plated in coculture, tubule formation occurred by 72 hours and was maximal at 14 
days in vitro (control human smooth muscle cells, hepatocytes, monocytes, and epithelial 
cells failed to form tubes). The ability of these endothelial cell lines to form tubes was direct 
contact– dependent, stimulated by VEGF, and inhibited by anti-VEGF antibody or suramin 
addition to the cocultures. While the putative EPCs failed to form tubes in this assay, the 
circulating outgrowth endothelial cells displayed tubulogenesis properties with the same 
kinetics as the primary human endothelial cells. Of interest the putative EPCs displayed the 
ability to augment primary endothelial cell tubulogenesis in the cocultures in a dose 
dependent noncontact manner, whereas the outgrowth endothelial cells did not display this 
activity. However, only the outgrowth endothelial cells possessed the ability to integrate into 
networks of forming tubules (established using primary endothelial cells) compared to the 
putative EPCs that were unable to integrate into these endothelial networks. These results 
are strikingly similar to those described above, by our group and others,13,15,49 for the 
Hirschi et al. Page 6
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2017 January 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
activity displayed by ECFC in the in vivo vessel forming assay and the lack of this activity 
displayed by CFU-Hill (Figures 1 and 2).
In sum, the properties that appear to be shared among all the in vitro adherent cell types 
described above are the expression of endothelial markers (KDR, CD34, vWF, eNOS, 
vascular endothelial cadherin, and others) under rather specific culture conditions. However, 
those cells that also coexpress CD45, CD14, or CD115 among other markers ingest bacteria, 
display limited proliferative ability, and do not form human vessels de novo in vivo are 
derivatives of the marrow-derived hematopoietic system and are not EPCs, while those cells 
that do not express CD45, CD14, or CD115 do not ingest bacteria, display high proliferative 
potential at a clonal level, and form in vitro tubules in coculture with human fetal lung 
fibroblasts or directly form human vessels de novo in vivo are reflecting those properties that 
best define a functional EPC (Figure 2).13 The origin of these latter high proliferative 
endothelial cells remains obscure, as both marrow-derived and widespread vessel-derived 
origins have been proposed.40,42 Thus, more extensive analyses of the cells displaying the 
morphology of endothelial cells in vitro has permitted a growing list of properties that can 
be used to discriminate hematopoietic-derived cells, such as monocyte-macrophages that 
have a remarkable potential to display an endothelial morphology and gene expression 
pattern, from ECFC which display all of the phenotypic and functional properties of true 
EPCs.
Cell Surface Markers to Identify EPCs
As noted above, there is currently, to our knowledge, no specific identifying marker for 
human or murine EPCs. To trace the origin of how the many different human EPCs 
phenotypes emerged in the literature, we must start with the seminal article by Asahara et 
al10 who postulated that use of available antibodies to known proteins expressed on 
embryonic angioblasts and HSC might permit a method to isolate EPCs (presumably an 
adult angioblast). CD34 was an obvious starting molecule of interest, because it is widely 
recognized as the principal marker used to isolate HSC for human clinical stem cell 
transplantation.55,56 CD34 is a sialomucin expressed on a variety of mesoderm progeny 
including blood, endothelial, and fibroblast cells and by numerous epithelial lineages and 
some cancer stem cell populations. KDR (human) or Flk-1 (mouse), a receptor for vascular 
endothelial growth factor, is also widely expressed on mesoderm derived lineages including 
blood, endothelium, and cardiac tissues.57 Although the original studies reported by Asahara 
et al10 used minimally enriched populations (15% to 20%) of CD34+ and Flk-1+ cells to 
initiate cultures of adherent cells, the cells present in those cultures were found to localize to 
areas of neoangiogenesis in vivo. This association led the authors to state that circulating 
CD34+ and Flk-1+ mononuclear blood cells may contribute to neoangiogenesis in adult 
species, and this cell surface antigen pair formed the first putative marker set for identifying 
the EPCs (Figure 2). However, no direct evidence was presented in the manuscript to 
confirm that highly purified cells expressing only one or the other or both antigens directly 
participated in neoangiogenesis or became integrated into the endothelial intima.
Pursuing the question of the origin of cells within the bloodstream that colonized 
experimentally implanted Dacron grafts, Shi et al58 and Bhattacharya et al59 tested the 
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question that circulating EPCs may be the source. It had been reported for several decades 
that many implanted grafts can become colonized with an intact endothelial cell monolayer 
that was host derived.60,61 To define whether the circulating cells colonizing these grafts 
were simply sloughed mature endothelial cells from nearby sites, circulating EPCs 
(presumably derived from the endothelial intima), or EPCs derived from the marrow, Shi et 
al58 performed bone marrow transplantation in dogs (with defined alleles determined by 
polymerase chain reaction (PCR)-microsatellite analysis) and observed that donor marrow-
derived cells entered the circulation and colonized implanted vascular prostheses (the cells 
lining these grafts expressed CD34). Because human CD34+ cells isolated by monoclonal 
antibody and immunomagnetic beads demonstrated the ability to give rise to adherent 
colonies of rapidly proliferating endothelial cells after 15 to 20 days in vitro, the authors 
interpreted their data to suggest that a subset of CD34+ cells localized in the marrow could 
be mobilized to the peripheral circulation and colonize the intraluminal exposed surfaces of 
vascular prostheses. However, the authors correctly stated that formal proof of this 
hypothesis awaited further studies in which individual endothelial cells colonizing the 
implanted graft could be proven to be derived from a single marrow-derived CD34+ cell.
Using a similar experimental canine model of graft implantation, Bhattacharya et al59 
reported that preoperative seeding of Dacron grafts with marrow-derived CD34+ cells 
appeared to facilitate the colonization and seeding of the grafts with endothelial-like cells, 
though there was no correlation between the number of seeding CD34+ cells and the degree 
of endothelial-like coating of the luminal surface of the grafts. Again the authors pointed out 
that only by labeling the marrow-derived CD34+ cells with a long-lasting marker could they 
provide definitive proof that the enhancement of the colonization of the grafts with 
endothelial cells originated from the CD34+ cells. Thus, neither of the above articles directly 
provided evidence that CD34+ cells directly differentiate into endothelial cells or directly 
form new blood vessels in vivo; the CD34 containing cell populations certainly appeared to 
be associated with these events but not necessarily directly involved, and thus CD34+ cells 
were never directly proven to be EPCs in these articles.
To test the question of whether the circulating human CD34+ cells represent sloughed 
mature endothelial cells or circulating EPCs, Peichev et al62 attempted to define a panel of 
cell surface antigens that may better define the difference between circulating endothelial 
cells (CECs) and EPCs. Rationalizing that EPCs may share some cell surface antigen 
expression patterns with HSCs, Peichev et al62 chose to characterize the functional 
characteristics of cells separated by expression patterns for CD34, KDR, and CD133. 
CD133 (AC133, prominin-1) originally identified on neuroepithelial cells, is a 5-
transmembrane domain cell-surface glycoprotein that localizes to membrane protrusions on 
numerous epithelial, hematopoietic, and various cancer stem cells.63 Because CD34 and 
CD133 were known to be highly expressed on HSCs but are downregulated with 
hematopoietic cell differentiation, Peichev et al62 rationalized that any cells coexpressing 
these molecules may represent an immature progenitor population. Furthermore, they tested 
the hypothesis that KDR (known to be expressed by embryonic angioblasts) may be 
coexpressed on subsets of CD133+ cells and could be used to discriminate between mature 
endothelial cells and circulating EPCs. The authors reported that mobilized adult peripheral 
blood, umbilical cord blood, and human fetal liver samples all contained rare populations of 
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CD34+KDR+ cells. Although 2% of the mobilized peripheral blood CD34+ cells 
coexpressed KDR and CD133, low passage CD34+KDR+ human umbilical vein endothelial 
cells (cells thought to represent mature differentiated vascular endothelium) did not express 
CD133, and these data were interpreted as evidence that the circulating 
CD34+KDR+CD133+ cells may represent a population of cells with progenitor properties; a 
putative EPC phenotype. Additional flow cytometric analysis demonstrated that 
CD34+KDR+ cells coexpressed E-selectin, vascular endothelial cadherin, CXCR4, CD31, 
and CD13 but not the myelomonocytic markers CD15 or CD14 (CD45 expression was not 
mentioned). To quantify the ability of the KDR+ cells to form endothelial cells in vitro, 
CD34+ cells isolated from human fetal liver were cultured with VEGF and FGF-2 for 48 
hours. Nonadherent KDR+ cells were isolated by KDR antibody and immunomagnetic beads 
and plated in limiting dilution. After nearly 2 weeks, 15 colonies of endothelial cells were 
obtained from 500 KDR+ plated cells suggesting that most colonies obtained in those culture 
wells contained more than one plated initiating cell and suggested a role for accessory cells 
in facilitating colony formation. To confirm the presence of CD133 and KDR expressing 
cells in vivo, Peichev et al62 examined the luminal surfaces of implanted left ventricular 
assist devices in human subjects and identified 3% of the mononuclear cells on the luminal 
surface coexpressing CD133 and KDR. Based on this evidence, the authors concluded that 
EPCs could be defined as circulating CD34+ cells that coexpressed CD133 and KDR, and 
they proposed that quantification of these cells in the peripheral circulation may provide 
useful information regarding the role of EPCs in different disease states. However, no direct 
evidence was presented in the article that isolated and purified human circulating 
CD34+KDR+CD133+ cells directly participate in generating the endothelial lining of the 
implanted left ventricular device or formed endothelial cells at a clonal level in vitro; 
nonetheless, this phenotype has largely been accepted as representative of a human 
circulating EPCs (Figure 2).
While thousands of articles have been published since 2000 using some combination of 
CD34, CD133, or KDR with or without other markers such as CD31 and Tie 2 (in mice) to 
identify circulating EPCs, and many of the articles have reported statistically significant 
correlations between the blood concentration of the selected putative EPC subset and a 
disease state, few had attempted to formally compare the functional properties of isolated 
human circulating CD34+KDR+CD133+ cells in hematopoietic and endothelial assays. We 
have recently isolated this triple positive population of cells from umbilical cord blood or 
mobilized adult peripheral blood and reported that purified CD34+ KDR+CD133+ cells are 
highly enriched in hematopoietic progenitor activity but do not give rise to any ECFC 
colonies in vitro.64 Perhaps not surprising given all the rationale in the above studies, more 
than 99% of the CD34+KDR+CD133+ cells coexpress CD45, the common leukocyte antigen 
(this antigen is not expressed in endothelial cells even at the mRNA level).64 In fact, if cord 
blood CD34+CD45− cells were isolated and plated, ECFC were enriched 368-fold compared 
to unfractionated mononuclear cells, and no ECFCs were detectable in cultures established 
with CD34+CD45+ cells. Thus, the CD34+KDR+CD133+ cells from mobilized adult 
peripheral blood and human umbilical cord blood are devoid of the cells that display the in 
vitro and in vivo properties of an EPC (Figure 2).
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Timmermans et al46 have also reported that colonies of endothelial cells that display high 
proliferative potential are derived only from a human cord blood or bone marrow 
CD34+CD45− population of cells and not from CD34+CD45+ cells (which were enriched for 
hematopoietic colony forming cells). Of interest the CD34+CD45− population of cells, 
which gave rise to colonies of endothelial cells with high proliferative potential, also 
expressed KDR but not CD133, whereas the CD34+CD45+ cells enriched for hematopoietic 
cells coexpressed CD133 but not KDR. Thus, several labs have independently determined 
that the EPCs which give rise to colonies of high proliferative endothelium are not derived 
from cells expressing CD133 or CD45 (Figure 2).
In summary, no one has yet reported a specific marker to prospectively isolate human EPCs. 
In the earliest studies (1997 to 2000) describing the properties of putative EPCs, a number of 
antigens that were known to be coexpressed by the hematopoietic system were chosen as 
possible markers that could be used in combination to identify circulating EPCs. In fact, 
those markers (CD34+KDR+CD133+) highly enrich for hematopoietic progenitor cells (as 
predicted) but fail to specifically isolate ECFCs. Nonetheless, CD34+ KDR+CD133+ cells 
and cells isolated with any combination of these markers appear to play an important role in 
neoangiogenesis in many human disease states and are predictive biomarkers for some.65–69 
Thus, the field has advanced in our understanding of the role of multiple cell types in the 
process of neoangiogenesis, despite the fact that in many cases, the cells examined as 
putative EPCs were most likely hematopoietic lineage derivatives (Figure 2).
Now we can go forward and begin to understand the specific functional roles that each of the 
numerous cell types play in normal and abnormal blood vessel formation. Of interest, 
attention now may be refocused to better understand the phenotype and proliferative 
behavior of endothelial cells lining all vascular structures,42 where the quiescent 
endothelium may harbor a putative pool of cells with proliferative potential for 
neoangiogenesis, which can be modulated by the influx of recruitable, circulating, and 
activation dependent bone marrow-derived hematopoietic lineages.
Potential of EPCs
Despite the fact that the origin and phenotype of EPCs within blood circulation and marrow 
have yet to be definitively resolved, and further work is greatly needed in this area, there is a 
significant amount of ongoing experimentation intended to test, in vitro and in vivo, the 
vascular potential of putative EPC populations isolated using various methodologies. 
Therefore, to gain further insights from these studies and understand the potential and 
function of each population in postnatal vasculogenesis, it is imperative that appropriate and 
reliable methods are used to assess and quantify their distinct (or common) contributions. 
Only from such understanding can we develop and optimize clinical strategies to control 
postnatal vasculogenesis.
Distinguishing EPCs from mature functional endothelial cells and hematopoietic cells based 
on cell surface marker expression alone is challenging, as discussed above, because many 
markers are commonly expressed among these cell types. Perhaps this is not surprising 
given that some of the putative EPC populations currently studied may, in fact, be 
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hematopoietic cells, and others are thought to be derived from endothelium. Thus, 
demonstrating that a specific population of putative EPCs does, in fact, have the capacity to 
differentiate into mature functional endothelial cells in vitro and in vivo requires the 
assessment of multiple parameters, including morphology, behavior, in situ localization, and 
gene/ protein expression.
Morphology In Vitro
In 2-dimensional culture systems, EPCs proliferate rapidly and form multidimensional 
colonies, with mixed morphology including rounded clusters associated with adherent 
spindle-shaped cells.12,41 In contrast, endothelial cells grow in mono-layers in vitro, become 
growth inhibited on reaching confluence, and exhibit so-called “cobblestone” morphology.70 
Thus, the distinction among these cell types in vitro should not be difficult, and 
demonstrating that a specific EPC population takes on an endothelial cell phenotype should 
be achievable by monitoring morphology. However, some EPC populations are selected 
based on their “adherence” properties, and they grow as monolayers with morphology 
similar to endothelial cells. Thus, in general, morphology alone is not a useful indicator to 
demonstrate that EPCs have “differentiated” into endothelial cells. The comonitoring of 
contact-induced growth inhibition would be advantageous but is seldom done. In contrast, 
other tests that have similar problems as the monitoring of morphological changes are 
frequently used to demonstrate that putative progenitors have endothelial cell potential, 
including uptake of DiI-labeled acetylated-low density lipoprotein (Ac-LDL)71 and binding 
of fluorescently labeled Ulex europaeus agglutinin 1 (UEA-1) plant lectin.72
Uptake of DiI-Ac-LDL
Acetylated-LDL is taken up by endothelial cells via the “scavenger cell pathway” of LDL 
metabolism. This property of endothelial cells was exploited more than 3 decades ago to 
specifically identify and isolate endothelial cells from mixed cultures of vascular endothelial 
and mural cells (vascular smooth muscle cells and pericytes) during their simultaneous 
isolation from intact blood vessels.71 It was found in these studies that if mixed cultures of 
endothelial and mural cells were incubated with Ac-LDL labeled with the fluorescent probe 
1,1′-dioctadecyl-3,3,3′,3′-tetramethyl-indocarbocyanine perchlorate (DiI-Ac-LDL, 10 
mg/mL for 4 hours at 37°C), then visualized by fluorescence microscopy, the endothelial 
cells were highly fluorescent because of internalization of the labeled LDL, and the mural 
cells exhibited fluorescence only slightly above background. This assay was then adopted as 
a means to identify endothelial cells and isolate them from surrounding mural cells in 
culture.
Since then, the DiI-Ac-LDL uptake assay has been used to demonstrate endothelial cell 
properties of EPCs, as well as to demonstrate that putative progenitor populations take on 
properties of functional endothelial cells. This has created quite a problem in the field 
because, as pointed out in the original study71 and in more recent studies,14,73 monocytes 
and macrophages also take up Ac-LDL via the scavenger pathway and thus have similar 
properties that have been mistakenly attributed specifically to endothelial cells. Because 
some of the putative EPC populations currently under investigation may, in fact, be derived 
from, or represent, myeloid lineage cells, their ability to internalize and digest Ac-LDL has 
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no relevance to endothelial cell phenotype or potential. Thus, this assay alone cannot be used 
to specifically identify an endothelial cell phenotype or to demonstrate endothelial cell 
functional properties of putative progenitors (Figure 2).
Binding of UEA-1 Lectin
Ulex europaeus I agglutinin (UEA-1) is a lectin specific for some α-L-fructose-containing 
glycocompounds and can be visualized by fluorescence microscopy. In early studies of 
human tissues, UEA-1 was found to bind predominantly to endothelial cells within blood 
vessel structures of all sizes.73 Thus, it became more widely used to identify this cell type in 
tissue sections and was later used in perfusion strategies to mark the luminal layer 
(presumably endothelial cells) of blood vessels in tissues in situ. However, it is not 
frequently noted that UEA-1 was also found to bind to epithelial cells in that early study73 
and a variety of other cell types including blood-derived cells in more recent studies.74–76 
Therefore, the binding of UEA-1 to a specific cell population does not, alone, indicate an 
endothelial cell phenotype. Furthermore, for reasons discussed above, binding of UEA-1 
combined with uptake of DiI-Ac-LDL cannot specifically distinguish functional endothelial 
cells from progenitors or hematopoietic cells (Figure 2). Other criteria, including gene/
protein expression, tube formation, and in vivo engraftment into functional blood vessels 
must be used to demonstrate that a putative EPC has true endothelial cell potential.
In Vitro Tube Formation
Endothelial cells cultured in 3-dimensional (3D) systems undergo vacuolization, elongation, 
and coalescence into tube-like structures with lumina, thereby recapitulating morphogenesis 
events that take place in vivo.77 The formation of tube structures in such 3D culture systems 
(usually composed of collagen or fibrin) appears to be unique to endothelial cells; however, 
many cell types are capable of forming cord-like structures in similar 3D systems. 
Therefore, when assessing the functional properties of putative endothelial progenitor 
populations, it is important to demonstrate the formation of bona fide tubes, and not just 
cord structures. The distinguishing feature is, of course, the presence of a lumen.
Formation of cords simply requires that the cells in culture line up, end to end or in layers, 
and stretch across the culture dish. Although endothelial cells can do this (Figure 3A), many 
other cell types can as well, including mammary epithelial cells (Figure 3B), which have no 
other phenotypic or functional similarity to endothelial cells. Tube formation, in contrast, is 
a much more complex process that requires vacuolization of cells in culture (Figure 3C; 
adapted from Davis et al78), a process thought to be specific to endothelial cells, and not 
shared by hematopoietic cell lineages, which are often mistaken for endothelial cells based 
on other criteria (cobblestone morphology, cell surface protein expression, Ac-LDL uptake, 
UEA-1 binding), as discussed above. Thus, when using in vitro vessel forming assays to 
demonstrate endothelial cell phenotype and function, it is critical to demonstrate the 
presence of a 3D structure with a lumen, and not just a 2-dimensional cord of cells.
The concept of growing endothelial cells in a collagen matrix came from the observation 
that in vivo, endothelial cells are constantly in contact with components of the extracellular 
matrix (ECM) and that for endothelial cells to take on a more in vivo phenotype they need to 
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be surrounded by ECM components.79 Because collagen is the major component of ECM, 
researchers decided to plate endothelial cells within collagen matrices and noted a drastic 
change in their morphology so that they resembled the microvasculature in vivo.79,80 In 
these initial experiments, the 3D matrices were produced by collagen coating flasks and 
plating bovine aortic endothelial cells on the surface of the gels. After the 3 days of culture, 
a second layer of collagen was poured on top of the endothelial cells. More recently, Davis 
and colleagues79,81 developed another 3D culture system that involves adding endothelial 
cells directly into collagen gels, and plating into microwells; after gelatinization is complete, 
culture media is applied.81 In this system, the coalescence of endothelial cells and 
progenitors thereof into tube structures (see Figure 3C), as well as the vacuolization of such 
cells, can be microscopically monitored in real time.
While collagen matrices are the most widely used in 3D endothelial tube forming assays, 
fibrin matrix has also been used. Fibrin is an elastic protein found in the blood that forms a 
fibrous network on conversion from fibrinogen, also found in blood plasma. This process 
normally occurs during blood coagulation, thus the fibrin matrix is frequently used when 
recreating an injury response model. The process of making a fibrin gel involves suspending 
endothelial cells in a mixture of plasminogen-and urokinase plasminogen activator (uPA)-
free human fibrinogen (in serum free medium). Thrombin is added and the mixture is 
aliquoted into the desired culture dish and allowed to clot. Serum containing endothelial cell 
media plus angiogenic factors is then added to the cultures, whereupon endothelial tube-like 
structures are observed to form.82,83 Collagen and fibrin matrices have been very 
informative with regard to the molecular regulation of endothelial cell tube formation. In 
addition, other cell types typically do not form tubes in such matrices; thus, the endothelial 
potential of putative progenitors can be reliably tested in these 3D systems.
An example of the power of such systems is demonstrated in the study done by Sieveking et 
al,54 as previously discussed. In these studies, they develop an in vitro tubulogenesis assay 
that highlights striking differences in the properties of putative EPCs as described by 
Asahara et al10 and outgrowth endothelial colonies (emerging 14 to 21 days after initial 
plating of blood mononuclear cells) with high proliferative potential described by Lin et al.40 
Whereas the putative EPCs failed to form tubes, the circulating outgrowth endothelial cells 
formed tubes with the same kinetics as primary human endothelial cells. The putative EPCs 
also displayed the ability to augment primary endothelial cell tubulogenesis in the cocultures 
in a dose dependent noncontact manner, whereas the outgrowth endothelial cells did not 
display this activity. However, only the outgrowth endothelial cells integrated into networks 
of forming tubules (established using primary endothelial cells) compared to the putative 
EPCs that were unable to integrate into these endothelial networks. Thus, the above studies 
demonstrate the usefulness of tubulogenesis assays in distinguishing progenitors with 
endothelial cell potential (Figure 2).
Vascular Engraftment In Vivo
Although in vitro tube formation assays can reveal the endothelial potential of specific cell 
populations, the most rigorous test of true potential of putative progenitors is engraftment 
into, or de novo formation of, functional blood vessels in vivo. There are a variety of animal 
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models used to test the endothelial potential of putative progenitors including, but not 
limited to, intravenous injection into injured animals, direct injection into injured tissues, 
and implantation of cells of interest within a matrix or tumor environment. Although all of 
these systems have distinct biological advantages and disadvantages, all are equally useful 
with regard to determining whether a specific target cell population can contribute to 
postnatal neovascularization. For this purpose, it is imperative that, in all models, the target 
population be distinguishable from endogenous vascular cells, so that one can determine 
whether, and quantify to what extent, the putative progenitors incorporate into the existing 
vasculature. This can be achieved in a number of ways such as by transplanting or 
implanting putative progenitors from genetically marked (ie, eGFP- or LacZ-expressing) 
donors into nonmarked genetically matched recipients.84,85 Putative progenitors from wild-
type animals can also be prelabeled with a fluorescent dye86 or transduced with a viral-
driven fluorescent reporter.87 Prelabeling the cells of interest then allows for careful 
microscopic examination of vasculature within the injured or implantation site to determine 
whether they are engrafted into the endothelium or mural cell layer of blood vessels. 
Analysis of thick (50 to 70 um) sections via confocal imaging, image analysis, and 3D 
image reconstruction allows for the clearest determination of engraftment into vessel 
structures, as opposed to association of putative progenitors with luminal or vessel wall 
cells. Perhaps this point can be best represented by the controversies surrounding the 
putative role for bone marrow–derived EPCs contributing to tumor angiogenesis. As 
discussed, the use of careful high-resolution multichannel (sequential) confocal microscopic 
scanning of tissues capable of visualizing 3D vascular structures and identifying whole 
single cells is required to definitively determine that bone marrow–derived cells migrate into 
periendothelial locations and rarely, if ever, differentiate into endothelial cells.88
Importantly, residence in the endothelial cell layer alone is not indicative of “differentiation” 
of putative progenitors into functional endothelial cells. To demonstrate that a phenotypic 
change has taken place in vivo, it is critical to assess the expression of genes/proteins 
indicative of mature, functional endothelial cells (ie, VE-cadherin, ICAM-2, vWF, eNOS). 
However, the expression of genes/proteins by the candidate progenitor population must be 
determined before choosing appropriate markers of their “differentiation” potential. Lack of 
such comparative analysis has caused problems in the field because several of the putative 
EPC populations under investigation express proteins thought to be endothelial-specific (ie, 
CD31, Tie-2) before injection or implantation, yet these same markers were used to assess 
“differentiation potential” posttransplantation. Thus, if putative EPCs are already expressing 
“endothelial-specific” proteins, then their expression thereof within the lining of vessels 
within a particular tissue or organ does not indicate that they have “differentiated” in vivo.
To summarize, although there are several assays currently used to determine whether a 
specific progenitor population has endothelial cell potential, the caveats of these individual 
tests must be considered. Some phenotypic characteristics and behaviors that are often 
specifically attributed to endothelial cells are, in fact, shared by other cell types, most 
notably myeloid cells and epithelial cells (Figure 4). Therefore, it is important to first 
understand the phenotype of the putative EPCs under investigation relative to mature 
endothelial cells and hematopoietic cells, and second to use a combination of parameters to 
assess true endothelial cell potential and function.
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Summary and Future Directions
We have taken a historic view of the EPC field, highlighting major findings, as well as 
sources of current controversies. We have restricted much of our focus to studies conducted 
in human subjects. When defining an EPC, at this time, one should attempt to encompass 
much of the vast array of data obtained from in vitro and in vivo experiments in animal 
models and in human subjects. The term as commonly used today, and in the broadest 
interpretation of the publications in the field, would indicate that a human EPC is a 
circulating cell that promotes neovascularization at sites of ischemia, hypoxia, injury, or 
tumor formation, and the circulating concentrations of the cells reflect various aspects of a 
host of diseases. As noted above, multiple cell types could play important roles in numerous 
stages of this process, and all would be contained within this definition. Thus, some of the 
cells may not become resident in the neovascular site but rather participate through largely 
paracrine effects, other cells may migrate through the endothelium to take up residence in 
periendothelial sites, and rare cells may have the capacity to incorporate into vessel intima 
and function as endothelial cells. Not surprisingly, this broad definition will lead to the kind 
of controversies currently afflicting the field because the types of cells being considered as 
EPCs vary widely from study to study. However, in the strictest sense of defining a cell that 
displays postnatal vasculogenic activity, a human EPC is a circulating cell that displays the 
ability to produce endothelial progeny that function to form endothelial tubes in vitro and 
contribute to the functional endothelial lining of injured or de novo emergent vascular 
structures in vivo. To date, the only cells that display this activity at a clonal level are human 
ECFCs. Thus, it is likely that all of the other cell types that participate in neoangiogenesis in 
some way initiate, facilitate, and regulate the process of ECFC capillary plexus formation 
and subsequent remodeling into arterial, venous, and capillary structures in vivo.
If the term EPC becomes restricted in usage to reference ECFCs, then what terms should be 
used to refer to all the other cells that participate in neovascularization? The best approach 
would be to strictly define all of the other cells involved in neovascularization by both 
phenotypic and functional properties. Therefore, if bone marrow–derived hematopoietic 
cells are recruited to a site of tumor neovascularization, one should attempt to define which 
hematopoietic lineages are present and determine the function of each of these subsets. 
Similar observations should be conducted during endothelial cell replacement after 
experimental or acquired endothelial denudation injury or the process of collateral arterial 
development in response to injury or increased metabolic demands. Obviously, the cells that 
participate in endothelial repair after a denudation injury, or neovascularization in response 
to a growing tumor, or collateral vessel development in response to a demand for increased 
blood flow to a tissue may all require different lineages or different proportions of cells with 
different kinetics of appearance and states of activation depending on the site, degree, and 
duration of the event. In fact, we have previously found that even the same cell type 
contributes differently to neovascularization depending on the mechanism of injury/stimulus 
for neovascularization.89
Once all the cells that play a specific role in postnatal vasculogenesis are defined, one can 
simply refer to the defined cell type rather than the term “EPC.” This approach will clarify 
the confusion surrounding the term EPC in its current usage. Indeed, it may be time to retire 
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the now nondescript term EPC and simply refer to the cells that form new vessels as ECFCs 
and the cells that modulate the process of neovascularization according to their defined 
properties and lineage of origin (monocyte, T lymphocyte, granulocyte-macrophage 
progenitor cell, etc).
To move this field forward, it will be imperative to more directly compare the cell 
populations involved in neovascularization in human subjects with those in rodent models in 
the context of similar physiological function, state of injury, or disease process. For example, 
it has been noted that the success in using EPCs to ameliorate cardiovascular injury after an 
experimental infarction in rodent models is much more effective in fostering improvement 
than the results obtained in many of the human clinical trials conducted to date.90 Some of 
this discrepancy may be related to differences in the human and rodent disease state 
examined (comparing responsiveness of older human subjects with chronic coronary arterial 
disease who subsequently suffer from myocardial infarction and receive stem cell infusions, 
with young healthy rodents that undergo acute experimental myocardial infarction prior to 
stem cell infusions), the cell populations studied (more extensive and comparative analysis 
of the morphology, state of activation, function, and phenotype of the many circulating cell 
types that have been called EPCs in mouse and man), and the general differences in levels of 
proliferative potential of both circulating and resident cells between mouse and man. All of 
these areas need to be more fully explored to better understand and optimize the treatment of 
human subjects with cells that have the capacity to regenerate and/or repair the vasculature 
in vivo.
References
1. Laubichler, MD., Aird, WC., Maienschein, J. The endothelium in history. In: Aird, WC., editor. 
Endothelial Biomedicine. New York: Cambridge University Press; 2007. p. 5-19.
2. Aird, WC. Introductory essay: The endothelium in health and disease. In: Aird, WC., editor. 
Endothelial Biomedicine. New York: Cambridge University Press; 2007. p. 1111-1112.
3. Bouvier CA, Gaynor E, Cintron JR, Bernhardt B, Spaet T. Circulating endothelium as an indication 
of vascular injury. Thromb Diath Haemorrh. 1970; 40:163–168.
4. Woywodt A, Blann AD, Kirsch T, Erdbruegger U, Banzet N, Haubitz M, Dignat-George F. Isolation 
and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a 
definition and a consensus protocol. J Thromb Haemost. 2006; 4:671–677. [PubMed: 16460450] 
5. Schatteman GC, Dunnwald M, Jiao C. Biology of bone marrow-derived endothelial cell precursors. 
Am J Physiol Heart Circ Physiol. 2007; 292:H1–H18. [PubMed: 16980351] 
6. Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler 
Thromb Vasc Biol. 2008; 28:208–216. [PubMed: 17951319] 
7. Kawamoto A, Losordo DW. Endothelial progenitor cells for cardiovascular regeneration. Trends 
Cardiovasc Med. 2008; 18:33–37. [PubMed: 18206807] 
8. Bertolini F, Mancuso P, Shaked Y, Kerbel RS. Molecular and cellular biomarkers for angiogenesis in 
clinical oncology. Drug Discovery Today. 2007; 12:806–812. [PubMed: 17933680] 
9. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in 
cancer; towards marker and target identification. Nat Rev Cancer. 2006; 6:835–845. [PubMed: 
17036040] 
10. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, 
Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 
275:964–967. [PubMed: 9020076] 
11. Ito H, Rovira II, Bloom ML, Takeda K, Ferrans VJ, Quyyumi AA, Finkel T. Endothelial progenitor 
cells as putative targets for angiostatin. Cancer Res. 1999; 59:5875–5877. [PubMed: 10606226] 
Hirschi et al. Page 16
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2017 January 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
12. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating 
endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 
348:593–600. [PubMed: 12584367] 
13. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, 
Ingram DA. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/
progenitor cell principals. Blood. 2007; 109:1801–1809. [PubMed: 17053059] 
14. Rhode E, Malischnik C, Thaler D, Maierhofer T, Linkesch W, Lanzer G, Guelly C, Strunk D. 
Blood monocytes mimic endothelial progenitor cells. Stem Cells. 2006; 24:357–367. [PubMed: 
16141361] 
15. Rohde E, Bartmann C, Schallmoser K, Reinisch A, Lanzer G, Linkesch W, Guelly C, Strunk D. 
Immune cells mimic the morphology of endothelial progenitor colonies in vitro. Stem Cells. 2007; 
25:1746–1752. [PubMed: 17395771] 
16. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, Dimmeler S. Increase in 
circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery 
disease. Circulation. 2001; 103:2885–2890. [PubMed: 11413075] 
17. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. 
Number and migratory activity of circulating endothelial progenitor cells inversely correlate with 
risk factors for coronary artery disease. Circ Res. 2001; 89:E1–E7. [PubMed: 11440984] 
18. Zhang SJ, Zhang H, Wei YJ, Su WJ, Liao ZK, Hou M, Zhou JY, Hu SS. Adult endothelial 
progenitor cells from human peripheral blood maintain monocyte/macrophage function throughout 
in vitro culture. Cell Res. 2006; 16:577–584. [PubMed: 16775629] 
19. Rehman J, Li J, Orschell CM, March KL. Peripheral blood “endothelial progenitor cells” are 
derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003; 
107:1164–1169. [PubMed: 12615796] 
20. Fernandez Pujol B, Lucibello FC, Gehling UM, Lindemann K, Weidner N, Zuzarte ML, 
Adamkiewicz J, Elsässer HP, Müller R, Havemann K. Endothelial-like cells derived from human 
CD14 positive monocytes. Differentiation. 2000; 65:287–300. [PubMed: 10929208] 
21. Ziegelhoeffer T, Fernandez B, Kostin S, Heil M, Voswinckel R, Helisch A, Schaper W. Bone 
marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res. 2004; 
94:230–238. [PubMed: 14656934] 
22. Schmeisser A, Garlichs CD, Zhang H, Eskafi S, Graffy C, Ludwig J, Strasser RH, Daniel WG. 
Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like 
structures in Matrigel under angiogenic conditions. Cardiovasc Res. 2001; 49:671–680. [PubMed: 
11166280] 
23. Schmeisser A, Graffy C, Daniel WG, Strasser RH. Phenotypic overlap between monocytes and 
vascular endothelial cells. Adv Exp Med Biol. 2003; 522:59–74. [PubMed: 12674211] 
24. Harraz M, Jiao C, Hanlon HD, Hartley RS, Schatteman GC. CD34-blood-derived human 
endothelial cell progenitors. Stem Cells. 2001; 19:304–312. [PubMed: 11463950] 
25. Hassan N, Campbell D, Douglas S. Purification of human monocytes on gelatin-coated surfaces. J 
Immunol Methods. 1986; 95:273–276. [PubMed: 3794346] 
26. Loomans CJ, Wan H, de Crom R, van Haperen R, de Boer HC, Leenen PJ, Drexhage HA, Rabelink 
TJ, van Zonneveld AJ, Staal FJ. Angiogenic murine endothelial progenitor cells are derived from a 
myeloid bone marrow fraction and can be identified by endothelial NO synthase expression. 
Arterioscler Thromb Vasc Biol. 2006; 26:1760–1767. [PubMed: 16728651] 
27. Bailey AS, Willenbring H, Jiang S, Anderson DA, Schroeder DA, Wong MH, Grompe M, Fleming 
WH. Myeloid lineage progenitors give rise to vascular endothelium. Proc Natl Acad Sci USA. 
2006; 103:13156–13161. [PubMed: 16920790] 
28. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L. Tie2 
identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation 
and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005; 8:211–226. [PubMed: 
16169466] 
29. De Palma M, Naldini L. Role of haematopoietic cells and endothelial progenitors in tumour 
angiogenesis. Biochim Biophys Acta. 2006; 1766:159–166. [PubMed: 16857321] 
Hirschi et al. Page 17
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2017 January 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
30. O’Neill TJ, Wamhoff BR, Owens GK, Skalak TC. Mobilization of bone marrow-derived cells 
enhances the angiogenic response to hypoxia without transdifferentiation into endothelial cells. 
Circ Res. 2005; 97:1027–1035. [PubMed: 16210550] 
31. Zentilin L, Tafuro S, Zacchigna S, Arsic N, Pattarini L, Sinigaglia M, Giacca M. Bone marrow 
mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not 
incorporated into the newly formed vessels. Blood. 2006; 107:3546–3554. [PubMed: 16391016] 
32. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, 
Heissig B, Hattori K, Zhang F, Hicklin DJ, Wu Y, Zhu Z, Dunn A, Salari H, Werb Z, Hackett NR, 
Crystal RG, Lyden D, Rafii S. Cytokine-mediated deployment of SDF-1 induces revascularization 
through recruitment of CXCR4+ hemangiocytes. Nat Med. 2006; 12:557–567. [PubMed: 
16648859] 
33. You D, Waeckel L, Ebrahimian TG, Blanc-Brude O, Foubert P, Barateau V, Duriez M, Lericousse-
Roussanne S, Vilar J, Dejana E, Tobelem G, Lévy BI, Silvestre JS. Increase in vascular 
permeability and vasodilation are critical for proangiogenic effects of stem cell therapy. 
Circulation. 2006; 114:328–338. [PubMed: 16847153] 
34. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, Chimenti S, Landsman L, 
Abramovitch R, Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and 
role of accessory cells. Cell. 2006; 124:175–189. [PubMed: 16413490] 
35. Okamoto R, Ueno M, Yamada Y, Takahashi N, Sano H, Suda T, Takakura N. Hematopoietic cells 
regulate the angiogenic switch during tumorigenesis. Blood. 2005; 105:2757–2763. [PubMed: 
15572584] 
36. Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, Markowitz D, Wu W, Liu C, Reisfeld 
RA, Xiang R. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J 
Clin Invest. 2006; 116:2132–2141. [PubMed: 16862213] 
37. Rafii S, Lyden D. A few to flip the angiogenic switch. Science. 2008; 319:163–164. [PubMed: 
18187643] 
38. Anghelina M, Krishnan P, Moldovan L, Moldovan NI. Monocytes/macrophages cooperate with 
progenitor cells during neovascularization and tissue repair: conversion of cell columns into 
fibrovascular bundles. Am J Pathol. 2006; 168:529–541. [PubMed: 16436667] 
39. Weiler, H., Sood, R. Endothelial mimicry of placental trophoblast cells. In: Aird, WC., editor. 
Endothelial Biomedicine. New York: Cambridge University Press; 2007. p. 1479-1487.
40. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial 
outgrowth from blood. J Clin Invest. 2000; 105:71–77. [PubMed: 10619863] 
41. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, Pollok K, Ferkowicz MJ, 
Gilley D, Yoder MC. Identification of a novel hierarchy of endothelial progenitor cells using 
human peripheral and umbilical cord blood. Blood. 2004; 104:2752–2760. [PubMed: 15226175] 
42. Ingram DA, Mead LE, Moore DB, Woodard W, Fenoglio A, Yoder MC. Vessel wall-derived 
endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial 
progenitor cells. Blood. 2005; 105:2783–2786. [PubMed: 15585655] 
43. Au P, Daheron LM, Duda DG, Cohen KS, Tyrrell JA, Lanning RM, Fukumura D, Scadden DT, 
Jain RK. Differential in vivo potential of endothelial progenitor cells from human umbilical cord 
blood and adult peripheral blood to form functional long-lasting vessels. Blood. 2008; 111:1302–
1305. [PubMed: 17993613] 
44. Gulati R, Jevremovic D, Witt TA, Kleppe LS, Vile RG, Lerman A, Simari RD. Modulation of the 
vascular response to injury by autologous blood-derived outgrowth endothelial cells. Am J Physiol 
Heart Circ Physiol. 2004; 287:H512–H517. [PubMed: 15072951] 
45. Gulati R, Jevremovic D, Peterson T, Chatterjee S, Shah V, Vile RG, Simari RD. Diverse origin and 
function of cells with endothelial phenotype obtained from adult human blood. Circ Res. 2003; 
93:1023–1025. [PubMed: 14605020] 
46. Timmermans F, Van Hauwermeiren F, De Smedt M, Raedt R, Plasschaert F, De Buyzere ML, 
Gillebert TC, Plum J, Vandekerckhove B. Endothelial Outgrowth Cells Are Not Derived From 
CD133+ Cells or CD45 + Hematopoietic Precursors. Arterioscler Thromb Vasc Biol. 2007; 
27:1572–1579. [PubMed: 17495235] 
Hirschi et al. Page 18
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2017 January 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
47. Nagano M, Yamashita T, Hamada H, Ohneda K, Kimura K, Nakagawa T, Shibuya M, Yoshikawa 
H, Ohneda O. Identification of functional endothelial progenitor cells suitable for the treatment of 
ischemic tissue using human umbilical cord blood. Blood. 2007; 110:151–160. [PubMed: 
17379743] 
48. Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, Oh BH, Lee MM, Park YB. 
Characterization of two types of endothelial progenitor cells and their different contributions to 
neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004; 24:288–293. [PubMed: 14699017] 
49. Melero-Martin JM, Khan ZA, Picard A, Wu X, Paruchuri S, Bischoff J. In vivo vasculogenic 
potential of human blood-derived endothelial progenitor cells. Blood. 2007; 109:4761–4768. 
[PubMed: 17327403] 
50. Guven H, Shepherd RM, Bach RG, Capoccia BJ, Link DC. The number of endothelial progenitor 
cell colonies in the blood is increased in patients with angiographically significant coronary artery 
disease. J Am Coll Cardiol. 2006; 48:1579–1587. [PubMed: 17045891] 
51. Yoon CH, Hur J, Park KW, Kim JH, Lee CS, Oh IY, Kim TY, Cho HJ, Kang HJ, Chae IH, Yang 
HK, Oh BH, Park YB, Kim HS. Synergistic neovascularization by mixed transplantation of early 
endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines 
and matrix metalloproteinases. Circulation. 2005; 112:1618–1627. [PubMed: 16145003] 
52. Bompais H, Chagraoui J, Canron X, Crisan M, Liu XH, Anjo A, Tolla-Le Port C, Leboeuf M, 
Charbord P, Bikfalvi A, Uzan G. Human endothelial cells derived from circulating progenitors 
display specific functional properties compared with mature vessel wall endothelial cells. Blood. 
2004; 103:2577–2584. [PubMed: 14630797] 
53. Shepherd BR, Enis DR, Wang F, Suarez Y, Pober JS, Schechner JS. Vascularization and 
engraftment of a human skin substitute using circulating progenitor cell-derived endothelial cells. 
Faseb J. 2006; 20:1739–1741. [PubMed: 16807367] 
54. Sieveking DP, Buckle A, Celermajer DS, Ng MKC. Strikingly different angiogenic properties of 
endothelial progenitor cell subpopulations. J Am Coll Cardiol. 2008; 51:660–668. [PubMed: 
18261686] 
55. Verfaillie C. Hematopoietic stem cells for transplantation. Nat Immunol. 2002; 3:314–317. 
[PubMed: 11919566] 
56. Bryder D, Rossi DJ, Weissman IL. Hematopoietic stem cells: the paradigmatic tissue-specific stem 
cell. Am J Pathol. 2006; 169:338–346. [PubMed: 16877336] 
57. Keller G. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. 
Genes Dev. 2005; 19:1129–1155. [PubMed: 15905405] 
58. Shi Q, Rafii S, Wu M, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR, 
Moore MA, Storb RF, Hammond WP. Evidence for circulating bone marrow-derived endothelial 
cells. Blood. 1998; 92:362–367. [PubMed: 9657732] 
59. Bhattacharya V, McSweeney PA, Shi Q, Bruno B, Ishida A, Nash R, Storb RF, Sauvage LR, 
Hammond WP, Wu MH. Enhanced endothelialization and microvessel formation in polyester 
grafts seeded with CD34+ bone marrow cells. Blood. 2000; 95:581–585. [PubMed: 10627466] 
60. Stump MM, Jordan GLJ, DeBakey ME, Halpert B. Endothelium grown from circulating blood on 
isolated intravascular Dacron hub. Am J Pathol. 1963; 43:361–369. [PubMed: 14057632] 
61. Wu MH, Shi Q, Wechezak AR, Clowes AW, Gordon IL, Sauvage LR. Definitive proof of 
endothelialization of a Dacron arterial prosthesis in a human being. J Vasc Surg. 1995; 21:862–
867. [PubMed: 7769746] 
62. Peichev M, Maiyer A, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, 
Moore MA, Rafii S. Expression of VEGFR-2 and AC133 be circulating human CD34(+) cells 
identifies a population of functional endothelial precursors. Blood. 2000; 95:952–958. [PubMed: 
10648408] 
63. Shmelkov SV, St Clair R, Lyden D, Rafii S. AC133/CD133/Prominin-1. Int J Biochem Cell Biol. 
2005; 37:715–719. [PubMed: 15694831] 
64. Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR, Bhavsar JR, Yoder MC, 
Haneline LS, Ingram DA. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor 
cells but distinct, primitive hematopoietic progenitors. Exp Hematol. 2007; 35:1109–1118. 
[PubMed: 17588480] 
Hirschi et al. Page 19
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2017 January 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
65. Urbich C, Dimmeler S. Endothelial progenitor cells: Characterization and role in vascular biology. 
Circ Res. 2004; 95:343–353. [PubMed: 15321944] 
66. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization 
and regeneration. Nat Med. 2003; 9:702–712. [PubMed: 12778169] 
67. Khakoo AY, Finkel T. Endothelial progenitor cells. Annu Rev Med. 2005; 56:79–101. [PubMed: 
15660503] 
68. Hristov M, Fach C, Becker C, Heussen N, Liehn EA, Blindt R, Hanrath P, Weber C. Reduced 
numbers of circulating endothelial progenitor cells in patients with coronary artery disease 
associated with long-term statin treatment. Atherosclerosis. 2007; 192:413–420. [PubMed: 
16837000] 
69. Hristov M, Weber C. The therapeutic potential of progenitor cells in ischemic heart disease-Past, 
present and future. Basic Res Cardiol. 2006; 101:1–7. [PubMed: 16382288] 
70. Gimbrone MA, Cotran R, Folkman JF. Human vascular endothelial cells in culture: growth and 
DNA synthesis. J Cell Biol. 1974; 60:673–684. [PubMed: 4363161] 
71. Voyta JC, Via DP, Butterfield CE, Zetter BR. Identification and isolation of endothelial cells based 
on their increased uptake of acetylated-low density lipoprotein. J Cell Biol. 1984; 99:2034–2040. 
[PubMed: 6501412] 
72. Suzuki K, Sakata N, Kitani A, Hara M, Hirose T, Hirose W, Norioka K, Harigal M, Kawagoe M, 
Nakamura H. Characterization of human monocytic cell line, U937, in taking up acetylated low-
density lipoprotein and cholesteryl ester accumulation A flow cyotmetric and HPLC study. 
Biochim Biophys Acta. 1990; 1042:210–216. [PubMed: 2302423] 
73. Holthofer H, Virtanen I, Kariniemi AL, Horima M, Linder E, Miettinen A. Ulex europaeus I lectin 
as a marker for vascular endothelium in human tissues. Lab Investigation. 1982; 47:60–66.
74. Schwechheimer K, Weiss G, Schnabel P, Moller P. Lectin target cells in human central nervous 
system and the pituitary gland. Histochemistry. 1984; 80:165–169. [PubMed: 6370930] 
75. Liu SM, Li CY. Immunohistochemical study of Ulex europaeus agglutinin 1 (UEA-1) binding of 
megakaryocytes in bone marrow biopsy specimens: demonstration of heterogeneity in staining 
pattern reflecting the stages of differentiation. Hematopathol Mol Hematol. 1996; 10:99–109. 
[PubMed: 8792151] 
76. Graziano M, St-Pierre Y, Potworowski EF. UEA-1-binding to thymic medullary epithelial cells 
selectively reduces numbers of cortical TCRalphabeta+ thymocytes in FTOCs. Immunol Lett. 
2001; 77:143–150. [PubMed: 11410246] 
77. Madri JA, Pratt BM. Endothelial cell-matrix interactions: in vitro models of angiogenesis. J 
Histochemistry Cytochemistry. 1986; 34:85–91.
78. Davis GE, Wonshill K, Stratman AN. Mechanisms controlling human endothelial lumen formation 
and tube assembly in three-dimensional extracellular matrices. Birth Defects Res. 2007; 81:270–
285.
79. Delvos U, Gajdusek C, Sage H, Harker LA, Schwartz SM. Interactions of vascular wall cells with 
collagen gels. Lab Investigation. 1982; 46:61–72.
80. Montesano R, Orci L, Vassalli P. In vitro rapid organization of endothelial cells into capillary-like 
networks is promoted by collagen matrices. J Cell Biol. 1983; 97:1648–1652. [PubMed: 6630296] 
81. Davis GE, Camarillo CW. An integrin-dependent pinocytic mechanism involving intracellular 
vacuole formation and coalescence regulates capillary lumen and tube formation in three-
dimensional collagen matrix. Exp Cell Res. 1996; 224:39–51. [PubMed: 8612690] 
82. Lafleur MA, Handsley MM, Knauper V, Murphy G, Edwards D. Endothelial tubulogenesis within 
fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-
MMPs). J Cell Sci. 2002; 115:3427–3438. [PubMed: 12154073] 
83. Bayless KJ, Davis GE. Sphingosine-1-phosphate markedly induces matrix metalloproteinase and 
integrin-dependent human endothelial cell invasion and lumen formation in three-dimensional 
collagen and fibrin matrices. BBRC. 2003; 312:903–913. [PubMed: 14651957] 
84. Jackson KA, Majka SM, Wang H, Pocius J, Hartley C, Majesky MW, Michael L, Entman M, 
Hirschi KK, Goodell MA. Regeneration of ischemic cardiac muscle and vascular endothelium by 
adult stem cells. J Clin Investigation. 2001; 107:1395–1402.
Hirschi et al. Page 20
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2017 January 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
85. Majka SM, Jackson KA, Kienstra KA, Majesky MW, Goodell MA, Hirschi KK. Distinct 
populations of vascular progenitors in skeletal muscle are bone marrow-derived and exhibit 
different cell fates during vascular regeneration. J Clin Investigation. 2003; 111:71–79.
86. Yoon CH, Hur J, Oh IY, Park KW, Kim TY, Shin JH, Kim JH, Lee CS, Chung JK, Park YB, Kim 
HS. Intercellular adhesion molecule-1 is upregulated in ischemic muscle, which mediates 
trafficking of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2006; 26:1066–1072. 
[PubMed: 16497992] 
87. Brunt KR, Hall SR, Ward CA, Melo LG. Endothelial progenitor cell and mesenchymal stem cell 
isolation, characterization, viral transduction. Methods Mol Med. 2007; 139:197–210. [PubMed: 
18287673] 
88. Purhonen S, Palm J, Rossi D, Kaskenpaa N, Rajantie I, Hla-Herttuala S, Alitalo K, Weissman IL, 
Salven P. Bone marrow-derived circulating endothelial precursors do not contribute to vascular 
endothelium and are not needed for tumor growth. Proc Natl Acad Sci USA. 2008; 105:6620–
6625. [PubMed: 18443294] 
89. Kienstra KA, Jackson KA, Hirschi KK. Mechanism and degree of injury dictate contribution of 
bone marrow-derived cells to neovascularization. J. Pediatric Research. 63:131–136.
90. Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, Craig R, Wen Y, Rapp JA, Kessler J. Clinical 
applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA. 
2008; 299:925–936. [PubMed: 18314435] 
Hirschi et al. Page 21
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2017 January 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Common methods of “EPC” culture. Culture of colony forming unit-Hill cells (CFU-Hill, 
Method A, scale bar=100 um), includes a 5-day process wherein nonadherent peripheral 
blood mononuclear cells (PB-MNCs) give rise to the colony. Circulating angiogenic cells 
(CAC, Method B, scale bar=200 um) are the adherent mononuclear cells of a 4- to 7-day 
culture of PB-MNCs. CAC cultures typically do not display colony formation. Endothelial 
colony forming cells (ECFCs, Method B, scale bar=400 um) are derived from adherent PB-
MNCs cultured for 6 to 21 days in endothelial conditions, and colonies display a 
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cobblestone morphology. Only the ECFC progeny form blood vessels de novo in vivo. 
Images were collected using a Zeiss Axiovert 2 inverted microscope with 10×/0.25Ph1 CP-
ACROMAT (CFU-EC), 32×/0.40Ph1 LD-ACROSTIGMAT (CAC), or 5× CP-ACHROMAT/
0.12Ph0 (ECFC) objectives. Images were acquired using a SPOT RT color camera 
(Diagnostic Instruments) with the manufacturer’s software. Images cropped and scale bars 
added in Adobe Photoshop version 8.0. Modified from Prater DN et al. Working hypothesis 
to redefine endothelial progenitor cells. Leukemia. 2007;21:1142.
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Figure 2. 
Characteristics of cells comprising the adherent population in the commonly used assays of 
“EPC” identification. Adherent cells that display the function are indicated by (+), that do 
not display the function by (−), and if the literature provides conflicting evidence (±). Those 
properties that distinguish cells in the ECFC assay from CFU-Hill and CAC assays are 
indicated in bold font. Only the ECFC and progeny display the full properties one would 
attribute to an EPC. VEGFR2 indicates vascular endothelial growth factor receptor 2; 
ALDH, aldehyde dehydrogenase; UEA-1, Ulex europeaus agglutinin-1; acLDL, acetylated 
low density lipoprotein; eNOS, endothelial nitric oxide synthase. The data for this figure are 
compiled from the articles referenced in this review.
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Figure 3. 
Cord and tube formation in vitro. Although endothelial cells (A; human embryonic stem 
cell-derived endothelial cells, Kelly and Hirschi unpublished) form cord structures in 
culture, so do other unrelated cell types, such as human mammary epithelial cells (B). Only 
endothelial cells undergo vacuolization and form tube structures with lumens that can be 
demonstrated in cross-section (C; human umbilical vein endothelial cells, adapted from 
Davis et al78).
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Figure 4. 
Characteristics of endothelial cells relative to myeloid and epithelial cells.
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